

UBIMOTIF

Newsletter 2

Jan 2022



Annual Meeting in Copenhagen 2021

Our first physical meeting for everyone in the network could finally take place in Copenhagen on 15-16 November 2021. With few exceptions, all UBIMOTIF members were present in Copenhagen, and it was a great opportunity to get to know each other.

The fellows had a nine-day program with workshops in addition to the annual meeting.



Our next Annual meeting will be in Jerusalem around 13-17 November 2022 (exact days and agenda to be announced).

First UBIMOTIF article in press

UBIMOTIF fellow Sophia Park from Matthias Peter lab at ETH Zurich, is co-author of the article "[The human GID complex engages two independent modules for substrate recruitment](#)" (Mohamed, et al, 2021) that was published in EMBO Reports in November 2021.

Remember to **acknowledge the EU funding** when the fellows are authors on a publication and to contact the project manager (Lotta Avesson) when you have a UBIMOTIF paper coming out so that we can spread the word!

Project and Consortium updates

The pandemic has continued to influence the project in 2021 and we see delays in the fellow's secondments and limited opportunities for outreach activities. We hope that these activities will be easier in 2022.

An amendment to the grant agreement was submitted in November 2021 and approved shortly after. The amendment includes a six-month extension of the project, *new end date is 31 May 2024*.

Other important points include:

- GSK has decided to terminate as beneficiary but intend to stay in the consortium as a partner organization. The GSK fellow will continue to participate in our training program as much as possible.
- Jason Brown and Ubiquigent has left UBIMOTIF as partner. Jason has moved on to a different company and there was no one who could fill his space as UBIMOTIF partner. Ubiquigent's role was advisory, and their termination does not directly affect our activities.

- A new research group at University of Copenhagen has joined UBIMOTIF and recruited one ESR that started in January 2022. Welcome to group leader Anders Bach and UBIMOTIF fellow Marie Cadot! Read more here about the Bach group here:
<https://drug.ku.dk/disciplines/medicinal-chemistry/bach-group/>

We are currently working on the Periodic Reporting that is covering the two first two years of the project.

Web and social media

<https://ubimotif.ku.dk/> for information about UBIMOTIF!

Follow UBIMOTIF and our fellows on Twitter and remember to tag us!



This project has received funding from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 860517